Physician profile
Jonathan C Uecker
NPI 1659334092
$7,962.71
in general payments reported to CMS, 2019-2025
11 companies · $28.01 in 2025
The $28.01 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.58 · 2020: $900 · 2021: $2,647 · 2022: $4,212 · 2024: $117 · 2025: $28.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $145.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $7,640.35 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $79.75 | 2019-2022 | |
| Tempus Ai, INC | $57.72 | 2024 | |
| Alkermes, INC. | $50.21 | 2022-2024 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $41.36 | 2024-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $28.55 | 2021-2022 | |
| Allergan, INC. | $14.10 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.63 | 2022 | |
| Corium, LLC | $12.49 | 2024 | Azstarys |
| Neurocrine Biosciences, INC. | $12.29 | 2021 | |
| Abbvie INC. | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Uecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.